GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback